guest ::
| 001 | 798313 | ||
| 005 | 20230215042541.0 | ||
| 024 | 7 | _ | |a G:(EU-Grant)864121 |d 864121 |2 CORDIS |
| 024 | 7 | _ | |a G:(EU-Call)ERC-2019-COG |d ERC-2019-COG |2 CORDIS |
| 024 | 7 | _ | |a corda__h2020::864121 |2 originalID |
| 035 | _ | _ | |a G:(EU-Grant)864121 |
| 150 | _ | _ | |a Macro-Nanomedicine to Treat Metastatic Cancer |y 2020-04-01 - 2025-03-31 |
| 371 | _ | _ | |a Universitätsklinikum Aachen |b UKA |d Germany |e http://www.ukaachen.de/ |v CORDIS |
| 372 | _ | _ | |a ERC-2019-COG |s 2020-04-01 |t 2025-03-31 |
| 450 | _ | _ | |a Meta-Targeting |w d |y 2020-04-01 - 2025-03-31 |
| 510 | 1 | _ | |0 I:(DE-588b)5098525-5 |a European Union |2 CORDIS |
| 680 | _ | _ | |a Metastatic cancer is a complex and highly heterogenous disease, which is very difficult to treat. The aim of the Meta-Targeting project is to establish a holistic, rational and realistic nanomedicine-based approach to improve the treatment of metastatic breast cancer. Concrete objectives are: (1) the development of polymeric micelles which can be efficiently and stably co-loaded with three different drugs and with an imaging agent; (2) the use of physical and pharmacological means to modulate the vasculature and microenvironment in tumors and metastases; (3) the identification of imaging- and biopsy-based biomarkers for patient selection; (4) the incorporation of drugs to overcome cellular and microenvironmental multidrug resistance; and (5) the implementation of multifunctional micelles to enhance the efficacy of immunotherapy. It is envisaged that micelles loaded with in-house developed doxorubicin prodrugs are able to induce immunogenic cell death in tumors and metastases without causing systemic immunodepression, that co-loading with the angiotensin receptor inhibitor losartan helps to prime tumors and metastases for improved delivery (of micelles, immunomodulatory antibodies and T cells), and that co-loading with the P-glycoprotein inhibitor tariquidar assists in inducing immunogenic cell death, while avoiding typical anti-Pgp side effects, such as neurotoxicity. Physical priming with ultrasound and microbubbles will promote the delivery of micelles, antibodies and T cells to and into primary tumors. Imaging- and biopsy-based biomarkers are needed to allow for patient stratification, which is critically important to improve the clinical translation of cancer nanomedicines. The outcomes of the different project lines in Meta-Targeting will - alone and especially together - be truly transformative: they will contribute to scientific and clinical progress in nanomedicine, in tumor-targeted drug delivery, in immunotherapy, and in the treatment of metastatic cancer. |
| 909 | C | O | |o oai:juser.fz-juelich.de:880760 |p authority:GRANT |p authority |
| 909 | C | O | |o oai:juser.fz-juelich.de:880760 |
| 970 | _ | _ | |a oai:dnet:corda__h2020::a893d0fb02a2e1e027f265e34e25d7b6 |
| 980 | _ | _ | |a G |
| 980 | _ | _ | |a CORDIS |
| 980 | _ | _ | |a AUTHORITY |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|